Published in

Wiley, British Journal of Dermatology, 1(170), p. 206-209

DOI: 10.1111/bjd.12572

Links

Tools

Export citation

Search in Google Scholar

Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis

Journal article published in 2014 by A. C. Foulkes, L. Wheeler, D. Gosal, C. E. M. Griffiths ORCID, R. B. Warren
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

A 49-year-old Caucasian male was referred to the Manchester Psoriasis Service with a 21-year history of severe chronic plaque psoriasis refractory to therapy with topical agents, phototherapy (TL-01), systemic agents (methotrexate, ciclosporin and fumaderm) and the biologic agents adalimumab and ustekinumab, including with concurrent ciclosporin therapy. Relevant history included alcohol excess. There was no family history of demyelination. Following a flare of psoriasis in June 2011, treatment was changed from ustekinumab (90mg dosing regimen) with ciclosporin 2mg/kg/day, to infliximab IV (5mg/kg at week 0, 2, 6, thereafter at 8 week intervals). This article is protected by copyright. All rights reserved.